Table 3.
Dysregulation of miRNAs as diagnostic and prognostic biomarkers of CRC.
| miRNAs | Sources of miRNA | Expression | Sensitivity | Specificity | Biomarker | References |
|---|---|---|---|---|---|---|
| miR-19a | Serum | up-regulation | 66.7% | 63.9% | Prognostic | [131] |
| miR-144 | Serum | up-regulation | 74% | 87% | Diagnostic | [132] |
| miR-106a | plasma | up-regulation | 62.3% | 68.2% | Diagnostic | [133] |
| miR-21 | Serum | up-regulation | 82.8% | 90.6% | Diagnostic and Prognostic | [47] |
| miR-601 | Plasma | down-regulation | 69.2% | 72.4% | Diagnostic | [134] |
| miR-18a | Serum | up-regulation | 61% | 69% | Diagnostic | [135] |
| miR-92 | Plasma | up-regulation | 89% | 70% | Diagnostic | [136] |
| miR-183 | Plasma | up-regulation | 73.7% | 88.5% | Diagnostic and Prognostic | [137] |
| miR-145 | Serum | down-regulation | – | – | Diagnostic and Prognostic | [138] |
| miR-23a-3p, miR-27a-3p, miR-142-5p, miR-376c-3p | Serum | up-regulation | 89% | 81% | Diagnostic | [139] |
| miR-92a | Plasma | up-regulation | 71.6% | 73.3% | Diagnostic | [136] |
| miR-451 | Plasma | up-regulation | 88.2% | 100% | Diagnostic | [140] |
| miR-139-3p, miR-431 | Plasma | up-regulation | 91% | 57% | Diagnostic and Prognostic | [141] |
| miR-96 | Plasma | up-regulation | 65.4% | 73.3% | Prognostic | [142] |
| miR-7, miR-93 | Plasma | down-regulation | 91% | 88% | Diagnostic | [143] |
| miR-17-3p | Plasma | up-regulation | 64% | 70% | Diagnostic and Prognostic | [138] |
| miR-760 | plasma | down-regulation | 80% | 72.4% | Diagnostic | [143] |
| miR-375 | Plasma | down-regulation | 76.92% | 64.63% | Diagnostic and Prognostic | [144] |
| miR-422a | Serum | down-regulation | – | – | Prognostic | [145] |
| miR-1290 | Serum | up-regulation | 70.01% | 91.2% | Diagnostic | [146] |
| miR-221 | plasma | up-regulation | 86% | 41% | Diagnostic | [135] |